Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

NHS England

This public procurement record has 2 releases in its history.

Award

06 Oct 2025 at 12:40

UK7 - Contract Details Notice
Award

01 Aug 2025 at 11:49

UK6 - Contract Award Notice
Summary of the contracting process

NHS England has completed an open procurement procedure for the NHS National Framework for Medical Retinal Vascular Treatments, scheduled to start on 1 December 2025. This procurement falls under the pharmaceutical products industry category and covers various regions in the United Kingdom, including North and South England, Midlands and East, and London. The contract is structured as a framework agreement with no reopening of competition, allowing for extensions up to 24 months at the authority's discretion. The procurement stage is now complete, with contracts signed on 22 September 2025 and the award valued in substantial figures, demonstrating NHS England's significant investment in retinal vascular treatments.

This procurement presents notable opportunities for businesses, particularly those in the pharmaceutical sector offering licensed medical retinal vascular anti Veg-F and intravitreal corticosteroid medicines. The framework seeks treatments for conditions such as neovascular age-related macular degeneration and diabetic macular oedema. Large pharmaceutical companies such as Abbvie Ltd, Bayer Plc, and Novartis Pharmaceuticals UK Ltd, as well as SMEs like Orion Pharma (UK) Ltd and Outlook Therapeutics, have been successful suppliers. This range of awarded suppliers highlights the framework's potential for both large and small companies to engage, fostering business growth through stable and lucrative long-term contracts with NHS England. Businesses capable of supplying innovative and effective medical treatments will find significant opportunities in this procurement process.

How relevant is this notice?

Notice Information

Notice Title

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Notice Description

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 Offer reference number: CM/PHS/25/5728 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National) 01/12/2025 to 31/05/2027 (18 months) CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg: NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months) SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months) MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months) LNW: (London) 01/12/2025 to 31/05/2027 (18 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; * neovascular (wet) age-related macular degeneration (AMD) * visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) * proliferative diabetic retinopathy (PDR) * visual impairment due to diabetic macular oedema (DME) * visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy * vision impairment associated with chronic diabetic macular oedema, (DME) * visual impairment due to myopic choroidal neovascularisation (myopic CNV) * retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease * inflammation of the posterior segment of the eye presenting as non-infectious uveitis * prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-055064
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/062482-2025
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£1,471,752,146 £1B-£10B
Contracts Value
£1,471,752,146 £1B-£10B

Notice Dates

Publication Date
6 Oct 202510 months ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
31 Jul 20251 years ago
Contract Period
1 Dec 2025 - 31 May 2027 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active, Pending
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Additional Buyers

NHS ENGLAND

Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LEEDS
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
Not specified
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
21
Supplier Names

ABBVIE LTD

ALIMERA SCIENCES LIMITED

Alimera Sciences

BAYER PUBLIC LIMITED COMPANY

BIOGEN IDEC LIMITED

Bayer Plc

Biogen

Biosimilar Collaborations Ireland Limited

CELLTRION HEALTHCARE UNITED KINGDOM LIMITED

MDBIOLOGICS LTD

NOVARTIS PHARMACEUTICALS UK LIMITED

Novartis Pharmaceuticals UK Ltd

ORION PHARMA (UK) LIMITED

Orion Pharma (UK) Ltd

Outlook Therapeutics, Inc.

ROCHE PRODUCTS LIMITED

Roche Products Ltd

SANDOZ LIMITED

TEVA UK LIMITED

THORNTON & ROSS LIMITED

Thornton and Ross Ltd

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...